Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

BACKGROUND: For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19 CAR-T cells may be ineffective due to anti-mouse single-chain variable fragment (scFv) antibody caused by mCD19 CAR. To overcome t...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Lihong, Lin, Yuehui, Deng, Biping, Yin, Zhichao, Zhao, Defeng, Ling, Zhuojun, Wu, Tong, Zhao, Yongqiang, Chang, Alex H., Tong, Chunrong, Liu, Shuangyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004014/
https://www.ncbi.nlm.nih.gov/pubmed/35410148
http://dx.doi.org/10.1186/s12885-022-09489-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004014/
https://www.ncbi.nlm.nih.gov/pubmed/35410148
http://dx.doi.org/10.1186/s12885-022-09489-1

Ejemplares similares